ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,930 shares of the specialty pharmaceutical company’s stock after selling 367 shares during the period. BNP Paribas Financial Markets’ holdings in ANI Pharmaceuticals were worth $473,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Pacer Advisors Inc. raised its stake in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after acquiring an additional 565,910 shares in the last quarter. Bank of Montreal Can bought a new position in shares of ANI Pharmaceuticals in the third quarter worth $13,043,000. Millennium Management LLC increased its holdings in shares of ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares during the period. Mizuho Markets Americas LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter valued at about $11,670,000. Finally, Assenagon Asset Management S.A. lifted its holdings in ANI Pharmaceuticals by 149.7% in the third quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after purchasing an additional 111,613 shares during the period. 76.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,731 shares of company stock worth $2,015,861. Company insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of recent analyst reports. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Raymond James increased their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Truist Financial increased their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Trading Up 0.1 %

ANI Pharmaceuticals stock opened at $56.59 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $51.79 and a 1 year high of $70.81. The firm’s 50 day moving average price is $58.01 and its two-hundred day moving average price is $60.33. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same period in the previous year, the firm posted $1.05 EPS. The company’s quarterly revenue was up 12.5% on a year-over-year basis. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.